AbbVie’s HUMIRA® (adalimumab) Approved by European Commission to Treat Paediatric Patients with Chronic Non-infectious Anterior Uveitis

Document -

AbbVie’s HUMIRA® (adalimumab) Approved by European Commission to Treat Paediatric Patients with Chronic Non-infectious Anterior Uveitis

Decision marks AbbVie’s HUMIRA® (adalimumab) as the only approved biologic treatment option in the European Union for paediatric patients from 2 years of age with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy
  • License: All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf

Contacts

General Press Enquiries

Press contact 01628 925200

Joanna Jones

Press contact Head of Brand Communications and Patient Relations 07795 590 344

Cheryl Pitcher

Press contact Senior Corporate Communications Manager Internal and Corporate Communications 07500 786 466

Natalie Bennett

Press contact Senior Communications and Patient Relations Manager Immunology - Gastroenterology & Rheumatology 07818 428 074

Sarah Beck

Press contact Senior Brand Communications and Patient Relations Manager, Dermatology Dermatology 07818 428 111

Related content

AbbVie’s HUMIRA® (adalimumab) Approved by European Commission to Treat Paediatric Patients with Chronic Non-infectious Anterior Uveitis

Decision marks AbbVie’s HUMIRA® (adalimumab) as the only approved biologic treatment option in the European Union for paediatric patients from 2 years of age with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy